KR100840957B1 - 글루코코르티코이드 관련 장애와 관련된 정신병을 치료하는방법 - Google Patents

글루코코르티코이드 관련 장애와 관련된 정신병을 치료하는방법 Download PDF

Info

Publication number
KR100840957B1
KR100840957B1 KR1020077003769A KR20077003769A KR100840957B1 KR 100840957 B1 KR100840957 B1 KR 100840957B1 KR 1020077003769 A KR1020077003769 A KR 1020077003769A KR 20077003769 A KR20077003769 A KR 20077003769A KR 100840957 B1 KR100840957 B1 KR 100840957B1
Authority
KR
South Korea
Prior art keywords
psychosis
psychotic
glucocorticoid receptor
receptor antagonist
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077003769A
Other languages
English (en)
Korean (ko)
Other versions
KR20070032822A (ko
Inventor
알랜 에프. 샤츠버그
조셉 케이 벨라노프
Original Assignee
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 filed Critical 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Publication of KR20070032822A publication Critical patent/KR20070032822A/ko
Application granted granted Critical
Publication of KR100840957B1 publication Critical patent/KR100840957B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077003769A 1997-10-06 1998-10-05 글루코코르티코이드 관련 장애와 관련된 정신병을 치료하는방법 Expired - Fee Related KR100840957B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6097397P 1997-10-06 1997-10-06
US60/060,973 1997-10-06
PCT/US1998/020906 WO1999017779A1 (en) 1997-10-06 1998-10-05 Methods for treating psychosis associated with glucocorticoid related dysfunction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020007003683A Division KR100804558B1 (ko) 1997-10-06 1998-10-05 글루코코르티코이드 관련 장애와 관련된 정신병을치료하는 방법

Publications (2)

Publication Number Publication Date
KR20070032822A KR20070032822A (ko) 2007-03-22
KR100840957B1 true KR100840957B1 (ko) 2008-06-24

Family

ID=22032889

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077003769A Expired - Fee Related KR100840957B1 (ko) 1997-10-06 1998-10-05 글루코코르티코이드 관련 장애와 관련된 정신병을 치료하는방법
KR1020007003683A Expired - Fee Related KR100804558B1 (ko) 1997-10-06 1998-10-05 글루코코르티코이드 관련 장애와 관련된 정신병을치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020007003683A Expired - Fee Related KR100804558B1 (ko) 1997-10-06 1998-10-05 글루코코르티코이드 관련 장애와 관련된 정신병을치료하는 방법

Country Status (17)

Country Link
US (2) US6150349A (https=)
EP (1) EP1023074B1 (https=)
JP (3) JP2001518509A (https=)
KR (2) KR100840957B1 (https=)
CN (3) CN1528315A (https=)
AT (1) ATE332696T1 (https=)
AU (1) AU747956B2 (https=)
CA (1) CA2302586C (https=)
CY (1) CY1106330T1 (https=)
DE (1) DE69835225T2 (https=)
DK (1) DK1023074T3 (https=)
ES (1) ES2268792T3 (https=)
IL (2) IL135469A0 (https=)
NO (1) NO327233B1 (https=)
NZ (1) NZ503250A (https=)
PT (1) PT1023074E (https=)
WO (1) WO1999017779A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
US7071328B2 (en) * 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)
DE60232956D1 (de) 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
WO2002096433A1 (en) * 2001-05-04 2002-12-05 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
CA2454339C (en) 2001-07-23 2012-01-10 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
NZ531477A (en) * 2001-08-31 2006-10-27 Corcept Therapeutics Inc Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome
DE60230936D1 (de) * 2001-10-26 2009-03-05 Organon Nv Verwendung von (11beta, 17beta)-11-(1,3-Benzodioxol-5-yl)-17-Hydroxy-17-(1-Propinyl)-estra-4,9-dien-3-on zur Behandlung von schweren Depressionen
AU2002366217A1 (en) * 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
JP2005535664A (ja) * 2002-07-02 2005-11-24 コーセプト セラピューティクス， インコーポレイテッド インターフェロン−α治療に関連した精神病を処置するための方法
WO2004054587A1 (en) * 2002-12-18 2004-07-01 University Of Zurich Treatment of neuro-psychiatric disorders
JP2006516651A (ja) * 2003-02-04 2006-07-06 コーセプト セラピューティクス， インコーポレイテッド 産後精神病の処置のための抗糖質コルチコイド
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US20090156565A1 (en) * 2004-12-03 2009-06-18 The Children's Hospital Of Philadelphia Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
CN100588393C (zh) * 2004-12-15 2010-02-10 上海三合生物技术有限公司 赛米司酮类用于治疗抑郁症的用途
US20060229505A1 (en) * 2005-04-08 2006-10-12 Mundt James C Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy
WO2007131041A2 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
EP1987814A1 (en) * 2007-04-30 2008-11-05 Exelgyn Mifepristone pharmaceutical compositions and their methods of preparation
RU2327448C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов
WO2008157460A1 (en) * 2007-06-15 2008-12-24 Cook, Kevin, M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
WO2011150209A1 (en) * 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
WO2012106514A2 (en) 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
AU2016226451B2 (en) * 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
KR20180008627A (ko) * 2015-05-18 2018-01-24 코어셉트 쎄라퓨틱스, 잉크. 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법
CN114680890A (zh) * 2016-10-21 2022-07-01 西铁城时计株式会社 检测装置
EP4653047A3 (en) 2019-03-18 2026-02-18 Nieman, Lynnette K. Mifepristone for use in improving insulin sensitivity
JP7569492B2 (ja) 2019-12-11 2024-10-18 コーセプト セラピューティクス， インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008588A1 (fr) * 1992-10-20 1994-04-28 Conservatoire National Des Arts Et Metiers Compositions pharmaceutiques contenant des derives de steroides naturels 3beta hydroxyles et leur utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
EP0954317B1 (en) * 1996-04-09 2007-06-06 The University Of Edinburgh Use of 7 apha-substituted steroids to treat neuropsychiatric disorders
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008588A1 (fr) * 1992-10-20 1994-04-28 Conservatoire National Des Arts Et Metiers Compositions pharmaceutiques contenant des derives de steroides naturels 3beta hydroxyles et leur utilisation

Also Published As

Publication number Publication date
NO327233B1 (no) 2009-05-18
PT1023074E (pt) 2006-12-29
CA2302586C (en) 2008-06-10
DE69835225T2 (de) 2007-07-05
AU9683298A (en) 1999-04-27
KR100804558B1 (ko) 2008-02-20
JP5180125B2 (ja) 2013-04-10
US6362173B1 (en) 2002-03-26
CA2302586A1 (en) 1999-04-15
DE69835225D1 (de) 2006-08-24
DK1023074T3 (da) 2006-11-06
CN1528315A (zh) 2004-09-15
KR20010024431A (ko) 2001-03-26
NO20001744L (no) 2000-04-05
IL135469A0 (en) 2001-05-20
NO20001744D0 (no) 2000-04-05
CN1919199A (zh) 2007-02-28
CN1272788A (zh) 2000-11-08
JP2001518509A (ja) 2001-10-16
AU747956B2 (en) 2002-05-30
IL135469A (en) 2007-03-08
KR20070032822A (ko) 2007-03-22
ATE332696T1 (de) 2006-08-15
EP1023074B1 (en) 2006-07-12
US6150349A (en) 2000-11-21
JP2009132743A (ja) 2009-06-18
JP2009051858A (ja) 2009-03-12
NZ503250A (en) 2001-09-28
CY1106330T1 (el) 2011-10-12
WO1999017779A1 (en) 1999-04-15
CN1187053C (zh) 2005-02-02
EP1023074A1 (en) 2000-08-02
ES2268792T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
KR100840957B1 (ko) 글루코코르티코이드 관련 장애와 관련된 정신병을 치료하는방법
KR100895662B1 (ko) 글루코코르티코이드 수용체 특이적 길항제를 이용한스트레스 장애의 치료 방법
JP2005501882A (ja) ダウン症候群を有する成人において認知低下を阻害する方法
US7884091B2 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
JP2009102346A (ja) グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
AU2002303652A1 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
AU2006233254B8 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
EP1726307A2 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
ZA200308910B (en) Method for treating delerium using glucocorticoid receptor-specific antagonists
HK1104214A (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
HK1059036B (en) Use of glucocorticoid receptor-specific antagonists for the treatment of delirium

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20130618

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20140618

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20150619

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150619

St.27 status event code: N-4-6-H10-H13-oth-PC1903